Cardio Diagnostics Holdings (CDIO) Operating Expenses (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Operating Expenses of $1.8 million for Q1 2026, up 21.87% sequentially from $1.5 million in Q4 2025, and up 9.56% YoY from $1.6 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Operating Expenses (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Operating Expenses for 6 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Operating Expenses rose 9.56% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (up 13.6% YoY) and the FY2025 annual result came in at $6.5 million, down 22.64% from the prior year.
- Operating Expenses climbed to $1.8 million in Q1 2026 per CDIO's latest filing, from $1.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $4.2 million in Q1 2024 and troughed at $232555.0 in Q1 2022.
- A 5-year average of $1.7 million and a median of $1.5 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 198127.71% in 2022, then slumped 60.91% in 2025.
- Over 5 years, Operating Expenses stood at $2.4 million in 2022, then slumped by 34.96% to $1.5 million in 2023, then decreased by 1.71% to $1.5 million in 2024, then declined by 3.56% to $1.5 million in 2025, then rose by 21.87% to $1.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.8 million, $1.5 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.79 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.63 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | 1.70 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 1.15 Mn |
| Jun 30, 2022 | 786,964.00 |
| Mar 31, 2022 | 232,555.00 |
| Dec 31, 2021 | 20,887.00 |
| Sep 30, 2021 | 721.00 |